Results 1 to 10 of about 1,439 (152)

Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context [PDF]

Biomedicines, 2021
Dalbavancin is a lipoglycopeptide approved for treatment of Gram-positive infections of skin and skin-associated structures (ABSSSI). Currently, off-label use at high dosages for osteoarticular infections deserves attention.
Giacomo Stroffolini, Francesco Giuseppe De Rosa, Antonio D'Avolio   +2 more
exaly   +4 more sources

Evaluating oritavancin for Gram-positive infections: a systematic review of on-label and off-label use [PDF]

Drugs in Context
Background: Oritavancin is a long-acting lipoglycopeptide antibiotic approved for acute bacterial skin and skin structure infections (ABSSSI) with potential applicability across difficult-to-treat Gram-positive infections such as osteomyelitis ...
Alex Soriano, Carlo Tascini, Marco Falcone, Laura Morata, Marco Bongiovanni, Federico Pea, Pierluigi Viale   +6 more
doaj   +3 more sources

Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)

Therapeutics and Clinical Risk Management, 2016
Kimberly D Leuthner,1 Kristin A Buechler,1 David Kogan,1 Agafe Saguros,1 H Stephen Lee2 1Department of Pharmaceutical Services, University Medical Center of Southern Nevada, Las Vegas, NV, USA; 2Roseman University of Health Sciences College of Pharmacy,
Leuthner KD, Buechler KA, Kogan D, Saguros A, Lee HS   +4 more
exaly   +3 more sources

Using Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) in Obese Patients: A Real-Life, Single-Center Observational Study [PDF]

Antibiotics
Background/Objectives: Obesity is an established risk factor for several infective conditions, including Acute Bacterial Skin and Skin Structure Infections (ABSSSIs), with a rising trend in their incidence expected in this population.
Alessandra Oliva, Flavia Petrucci, Cristiana Leanza, Marco Rivano Capparuccia, Michela Comi, Claudio Mastroianni   +5 more
doaj   +4 more sources

Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center [PDF]

Antibiotics, 2021
Dalbavancin is a lipoglycopeptide approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The aim of the study was to evaluate the efficacy and safety in all patients who received at least one administration of ...
Lucia Brescini, Filippo Della Martera, Gianluca Morroni, Sara Mazzanti, Maria Di Pietrantonio, Paolo Mantini, Bianca Candelaresi, Francesco Pallotta, Silvia Olivieri, Valentina Iencinella, Sefora Castelletti, Emanuele Cocci, Rosaria G. Polo, Salvatore Veccia, Oscar Cirioni, Marcello Tavio, Andrea Giacometti   +16 more
doaj   +3 more sources

Real-World Effectiveness of Dalbavancin in Osteomyelitis Without Implantable Devices: A Retrospective Monocentric Study [PDF]

Antibiotics
Background: Dalbavancin (DBV) is a long-acting lipoglycopeptide with activity against Gram-positive pathogens approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
Giorgio Tiecco, Angelica Lenzi, Federico Cesanelli, Evelyn Van Hauwermeiren, Francesco Rossini, Alessio Sollima, Alice Mulé, Silvia Lorenzotti, Liana Signorini, Francesco Castelli, Eugenia Quiros-Roldan   +10 more
doaj   +2 more sources

Omadacycline for the treatment of acute bacterial skin and skin structure infections: a systematic review and network meta-analysis [PDF]

BMC Infectious Diseases
Background Few studies have compared the efficacy and safety of omadacycline with other treatments for acute bacterial skin and skin structure infections (ABSSSI). Therefore, updated meta-analyses on this topic is necessary.
Wen-qiang Kong, Yun-feng Shu , Juan Tang, Shi-qin Li, Hong Zhong, Xuan-yi Zhang   +5 more
doaj   +2 more sources

Saving Beds and Budgets: Real-World Efficacy, Safety, and Pharmacoeconomics of Long-Acting Lipoglycopeptides (LALs) in a Day Hospital Setting [PDF]

Pathogens
Background: Long-acting lipoglycopeptides (LALs), including dalbavancin and oritavancin, may facilitate outpatient-oriented management of Gram-positive infections by reducing the need for prolonged hospitalization and daily intravenous therapy.
Andrea Marino, Emmanuele Venanzi Rullo, Giuseppe Pipitone, Alessandro Giorgio Geremia, Andrea De Vito, Antonio Albanese, Nicholas Geremia, Alessandro Franzò, Federica Cosentino, Paolo Italia, Maria Elena Ciuppa, Andrea Buzzi, Laura Santoro, Chiara Iaria, Giordano Madeddu, Carmelo Iacobello, Rosa Manuele, Fabrizio Pulvirenti, Bruno Cacopardo, Giuseppe Nunnari   +19 more
doaj   +2 more sources

Cost-analysis from real-world REDS study on dalbavancin in inpatient treatment of acute bacterial skin and skin structure infections [PDF]

Global & Regional Health Technology Assessment
Introduction: Inpatient treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) involves a significant economic burden on the healthcare system.
Matteo Scortichini, Alessandro Ruggieri, Agnese Cattaneo, Patrizia Mascagni, Paolo Sciattella   +4 more
doaj   +2 more sources

Dalbavancin in the Real-World Management of Gram-Positive Infections: A Systematic Review of Randomized and Observational Studies [PDF]

Microorganisms
Gram-positive infections are associated with significant morbidity and healthcare burden, often requiring prolonged intravenous therapy. Dalbavancin, a long-acting lipoglycopeptide, has emerged as a promising option beyond its approved indication for ...
Claudio Tana, Livia Moffa, Marco Tana, Samanta Moffa, Claudio Ucciferri   +4 more
doaj   +2 more sources